Akademik Veri Yönetim Sistemi
62nd ERA Congress , Vienna, Avusturya, 4 - 07 Haziran 2025, ss.3330, (Özet Bildiri)
INTRODUCTION
Immune checkpoint inhibitors (ICIs) have significantly
improved survival in various solid tumors. With the
increasing use of these agents, the number of
autoimmune toxicities—known as immune-related
adverse events (irAEs)—has risen.The incidence of
irAEs in patients receiving ICI therapy is estimated to
range between 60% and 85%.Renal irAEs are less
common compared to dermatologic, gastrointestinal,
and other organ toxicities.
RESULTS
AIM
This study aims to evaluate the incidence and
frequency of immune-related nephropathy among
patients treated with different ICIs, as reported in the
FDA adverse event reporting system (FAERS)
between 2020 and 2024.
METHOD
• The FDA Adverse Event Reporting System
(FAERS) is a publicly accessible database that
collects reports on adverse drug events.
• Data for this study were obtained from the publicly
available version of the FAERS database, covering
the period from January 2020 to December 2024..
• Five ICIs associated with immune-related
nephropathy were included in the analysis:
• AntiPD1agents: pembrolizumab and nivolumab
• Anti-PD-L1agents:atezolizumab,avelumab, and
durvalumab
• A total of 137,286 adverse events were
reported in the FAERS database between
January 2020 and December 2024.
• Immune-related nephropathy was identified
in 6,482 cases (4.7%).
• This condition was most frequently reported:
• In male patients (57.6%)
• In the 65–85 age group (50.9%)
• Distribution of immune-related nephropathy
by ICI (Figure 1):
✓ Pembrolizumab: 2,761 cases (5.1%)
✓ Nivolumab: 2,424 cases (5.3%)
✓ Durvalumab: 257 cases (2.2%)
✓ Atezolizumab: 928 cases (3.7%)
✓ Avelumab: 112 cases (4.7%)
• A statistically significant difference was
observed between individual ICIs (p < 0.01)
• A statistically significant difference in the
incidence of nephropathy was noted
between PD-1 and PD-L1 inhibitor groups
(5.2% vs 3.4%, p < 0.01) (Figure 2).
• No significant difference was found among
PD-1 inhibitors.
• A significant difference was found among
PD-L1 inhibitors;
✓ Avelumab vs Durvalumab: p < 0.01
✓ Avelumab vs Atezolizumab: p = 0.01
✓ Durvalumab vs Atezolizumab: p < 0.01
CONCLUSIONS
• ICI-associated acute kidney injury (ICI-AKI) is
a rare complication, reported in approximately
2–5% of patients receiving ICI therapy
• In our study, the frequency of renal irAEs was
found to be 4.7%
• Our study demonstrates significant variability
in the incidence of immune-related
nephropathy among different ICIs, with higher
frequencies observed in PD-1 inhibitors
• Among PD-L1 inhibitors, notable differences
were also detected, underscoring the
importance of vigilant renal monitoring during
ICI therapy